| Record ID | marc_loc_updates/v39.i51.records.utf8:20500044:1494 |
| Source | Library of Congress |
| Download Link | /show-records/marc_loc_updates/v39.i51.records.utf8:20500044:1494?format=raw |
LEADER: 01494cam a22003374a 4500
001 2011021601
003 DLC
005 20111216091608.0
008 110526s2011 flu b 001 0 eng
010 $a 2011021601
020 $a9781420091519 (hardcover : alk. paper)
035 $a(DNLM)101561527
040 $aDNLM/DLC$cDLC
042 $apcc
050 00 $aRM301.8$b.C44 2011
060 10 $aQV 771
082 00 $a615.1$223
100 1 $aCheung, Ying Kuen.
245 10 $aDose finding by the continual reassessment method /$cYing Kuen Cheung.
260 $aBoca Raton :$bTaylor & Francis,$c2011.
300 $axv, 189 p. :$bill. ;$c25 cm
490 1 $aChapman & Hall/CRC biostatistics series
504 $aIncludes bibliographical references (p. 179-186) and index.
505 0 $aDose finding in clinical trials -- The continual reassessment method -- One-parameter dose toxicity models -- Theoretical properties -- Empirical properties -- Specifications of a CRM design -- Initial guesses of toxicity probabilities -- Least informative normal prior -- Initial design -- The time-to-event CRM -- CRM with multiparameter models -- When the CRM fails -- Stochastic approximation.
650 0 $aDrugs$xDose-response relationship.
650 0 $aClinical trials.
650 12 $aClinical Trials, Phase I as Topic.
650 12 $aDose-Response Relationship, Drug.
650 22 $aBiostatistics$xmethods.
650 22 $aMaximum Tolerated Dose.
830 0 $aChapman & Hall/CRC biostatistics series ;$v41.